Experience of using a probiotic containing Lactobacillus reuteri B-9448 in children with acute infectious gastroenteritis
https://doi.org/10.31146/2949-4664-apps-2-1-104-112
Abstract
The article presents literature data on the relationship of disorders of the gastrointestinal tract with its microbiota in acute intestinal infections, as well as information on various beneficial properties of the probiotic microorganism Lactobacillus reuteri, including antagonistic effects on pathogenic and opportunistic pathogens, anti-inflammatory and immunomodulatory effects. The clinical and laboratory effectiveness of the use of a probiotic containing the Lactobacillus reuteri B-9448 strain in children with acute infectious gastroenteritis hospitalized. It was found that patients who received this probiotic in complex therapy spent significantly fewer bed days in the hospital compared to children who were not prescribed probiotic. At the same time, no undesirable side effects were registered in the group of patients treated with Lactobacillus reuteri B-9448, which indicates its safety.
About the Authors
S. G. Gorbunov
Research Clinical Institute of Childhood of the Moscow Region; “Russian Medical Academy of Continuous Professional Education” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
N. V. Gonchar
Children’s Research and Clinical Centre for Infectious Diseases, Federal Medical and Biological Agency of Russia; North-Western State Medical University named after I. I. Mechnikov
Russian Federation
Russian Federation
A. V. Bitsueva
Research Clinical Institute of Childhood of the Moscow Region; Krasnogorsk City Hospital № 2 of the Ministry of Healthcare of the Moscow region
Russian Federation
Russian Federation
References
1. Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor) in Moscow [Information on infectious and parasitic diseases for 2022. Form No 2.]. (In Russ.)@@ Сведения об инфекционных и паразитарных заболеваниях за 2022 г. Форма № 2. Управление Роспотребнадзора по г. Москве.
2. Mazankova L.N., Rybalchenko O. V., Nikolayeva I. V. [Microdysbiosis and endogenous infections (a guide for doctors)]. Moscow, 2018, 336 p. (In Russ.)@@ Мазанкова Л. Н., Рыбальченко О. В., Николаева И. В. Микродисбиоз и эндогенные инфекции (руководство для врачей). М:. 2018. - C. 336.
3. IPO EASID, Association of Infectious Disease Doctors of St. Petersburg and Leningrad Region. [Rotavirus gastroenteritis in children (clinical recommendations)]. Moscow, 2023, 45 p. (In Russ.)@@ Евро-Азиатское общество по инфекционным болезням, Ассоциация врачей-инфекционистов Санкт-Петербурга и Ленинградской области. Ротавирусный гастроэнтерит у детей (клинические рекомендации). М:. 2023. -C. 45.
4. Zakharova I.N., Dmitriyeva Yu. A. The intestinal microbiota and use of probiotics from the position of evidence-based medicine. Consilium Medicum. Pediatrics (Suppl.). 2016; 4: 24-28. (In Russ.)@@ Захарова И. Н., Дмитриева Ю. А. Кишечная микробиота и применение пробиотиков с позиции доказательной медицины. Consilium Medicum. Педиатрия. 2016; 4: 24-28.
5. Sarra P.G., Dellaglio F., Bottazzi V. Genetic heterogeneity among Lactobacillus acidophilus strains. Syst. Appl. Microbiol. 1985; 6: 86-99.
6. Reuter G. The Lactobacillus and Bifidobacterium Microflora of the Human Intestine: Composition and Succession. Curr Issues Intest Microbiol. 2001 Sep;2(2):43-53. PMID: 11721280.
7. Casas I.A., Dobrogosz W. J. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microbial. Ecol. Health Dis. 2000;12(4):247-285. doi: 10.3402/mehd.v12i4.8196.
8. Zakharova I.N., Berezhnaya I. V., Sugyan N. G., Sannikova Т. N., Kuchina A. E., Sazanova Yu. O. What do we know today about Lactobacillus reuteri? Meditsinskiy sovet = Medical Council. 2018;(2):163-169. (In Russ.) doi: 10.21518/2079-701X-2018-2-163-169.@@ Захарова И. Н., Бережная И. В., Сугян Н. Г. и др. Что мы знаем сегодня о Lactobacillus reuteri? Медицинский совет. 2018; 2: 163-169. doi: 10.21518/2079-701X-2018-2-163-169.
9. Afonyushkin V.N., Filipenko M. L., Shirshova A. N., Maslov O. G. [Mechanisms of biological activity of the Lactobacillus reuteri - reuterin system]. Problemy. Suzhdeniya. 2013; 4: 70-75. (In Russ.)@@ Афонюшкин В. Н., Филипенко М. Л., Ширшова А. Н., Маслов О. Г. Механизмы биологической активности системы Lactobacillus reuteri - реутерин. Проблемы. Суждения. 2013; 4: 70-75.
10. Axelsson L.T., Chung T. C., Dobrogosz W. J., Lindgren S. E. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microbial Ecology in Health and Disease. 1989; 2: 131-136.
11. Höltzel A., Gänzle M. G., Nicholson G. J., Hammes W. P., Jung G. The First Low Molecular Weight Antibiotic from Lactic Acid Bacteria: Reutericyclin, a New Tetramic Acid. Angew Chem Int Ed Engl. 2000 Aug 4;39(15):2766-2768. PMID: 10934421.
12. Castiblanco G.A., Yucel-Lindberg T., Roos S., Twetman S. Effect of Lactobacillus reuteri on cell viability and PGE2 production in human gingival fibroblasts. Probiotics and Antimicrobial Proteins. 2017; 9(Issue 3): 278-283. doi: 10.1007/s12602-016-9246-6.
13. Savino F., Zakharova I. N. Diagnosis and treatment of infantile colic: the experts ESPGHAN opinion. Consilium Medicum. Pediatrics (Suppl.). 2016; 2: 10-17. (In Russ.)@@ Савино Ф., Захаровa И. Н. Диагностика и лечение младенческих кишечных колик: мнение экcпертов ESPGHAN. Consilium Medicum. Педиатрия. 2016; 2: 10-17.
14. Mu Q., Tavella V. J., Luo X. M. Role of Lactobacillus reuteri in Human Health and Diseases. Front. Microbiol. 2018; 9: 757. doi: 10.3389/fmicb.2018.00757.
15. Rosander A., Connolly E., Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol. 2008 Oct;74(19):6032-40. doi: 10.1128/AEM.00991-08.
16. Ukraintsev S. E., Korniyenko E. A., Kafarskaya L. I., Dubrovskaya M. I. Microbes inside our bodies: casual companions, or prerequisite for our survival? Or why probiotics are needed in infant formulae. Pediatria n. a. G. N. Speransky. 2020; 99 (6): 163-171. (In Russ.) doi: 10.24110/0031-403X-2020-99-6-163-171.@@ Украинцев С. Е., Корниенко Е. А., Кафарская Л. И., Дубровская М. И. Микробы внутри нас: случайные попутчики или условие нашего выживания? Или зачем нужны пробиотики в детских молочных смесях. Педиатрия. Журнал им. Г. Н. Сперанского. 2020; 99(6): 163-171. doi: 10.24110/0031-403X-2020-99-6-163-171.
17. Gutierrez-Castrellon P., Lopez-Velazquez G., Diaz-Garcia L. et al. Diarrhea in preschool children and lactobacillus reuteri: a randomized controlled trial. Pediatrics. 2014; 133(4): 904-909. doi: 10.1542/peds.2013-0652.
18. Probiotics and prebiotics. WGO. Practical recommendations. 2008.
19. Komarova O. N. Efficacy of Lactobacillus reuteri in clinical practice.Russian Journal of Woman and Child Health. 2021;4(3):277-283 (in Russ.). doi: 10.32364/2618-8430-2021-4-3-277-283.@@ Комарова О. Н. Эффективность применения Lactobacillus reuteri в клинической практике. РМЖ. Мать и дитя. 2021; 4(3): 277-283.
Review
For citations:
Gorbunov S.G., Gonchar N.V., Bitsueva A.V. Experience of using a probiotic containing Lactobacillus reuteri B-9448 in children with acute infectious gastroenteritis. Archives of Pediatrics and Pediatric Surgery. 2024;2(1):104-112. (In Russ.) https://doi.org/10.31146/2949-4664-apps-2-1-104-112
Views:
694
Email this article 